logo
Plus   Neg
Share
Email

What Awaits Sesen Bio Tomorrow (Jan.3)?

sesen-jan02-lt.jpg

Shares of Sesen Bio Inc. (SESN) have gained nearly 48% over the last 5 trading days, as the Company gears up for updated data from its VISTA trial.

VISTA is a phase III trial of investigational drug Vicinium in patients with high-grade non-muscle invasive bladder cancer who have previously received two courses of bacillus Calmette-Guérin (BCG), the standard of care, and whose disease is BCG-unresponsive.

The trial involves 133 patients and 3 Cohorts.

On May 21, 2018, the Company reported encouraging three-month data from its VISTA trial, with Vicinium treatment demonstrating a complete response rate of 42 percent at three months. However, despite the encouraging data, Sesen shares tumbled 23% that day as investors were spooked by 4 treatment-related serious adverse events that were reported in the trial, including acute kidney injury or renal failure and cholestatic hepatitis.

The six-month data from the VISTA study is slated to be announced tomorrow, Thursday, January 3, 2019, at 8:30 a.m. ET.

The twelve-month data from the trial are anticipated in mid-2019.

SESN has traded in a range of $0.76 to $3.50 in the last 1 year. The stock closed Monday's (Dec.31, 2018) trading at $1.42, unchanged from the previous day's close.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT